Greenlane Holdings Inc

Análisis de la acción Greenlane Holdings Inc (GNLN)

$1.160

+0.020 (+1.75%)Al cierre

Loading chart…
Máximo
1.170
Apertura
1.130
Precio medio ponderado por volumen
1.15
Volumen
9.70K
Capitalización
1.31M
Mínimo
1.110
Importe
11.12K
EV/EBITDA, TTM
0.00

Greenlane Holdings, Inc. provides a global platform for the development and distribution of smoking accessories, vape devices, and lifestyle products to producers, processors, specialty retailers, smoke shops, convenience stores, and retail consumers. The Company operates as a family of brands, third-party brand accelerator, and an omnichannel distribution platform. The Company offers its own diverse brand portfolio and its licensed Marley Natural and K.Haring branded products. It also offers a set of third-party products through its direct sales channels and its proprietary, owned and operated e-commerce platforms. Its Greenlane Brands include Groove, its smoke shop and ancillary product brand - Higher Standards, and its child-resistant packaging brand - Pollen Gear. It merchandises vaporizers, packaging, and other ancillary products in the United States, Canada, Europe, and Latin America. Its third-party brands include Storz and Bickel, Grenco Science, PAX, and Cookies.

gnln.com

Análisis de IA of Greenlane Holdings Inc (GNLN)

Vender

Greenlane Holdings is not a good buy right now due to its current price of $1.14, a staggering year-to-date change of -90.98%, and an RSI of 9.42 indicating extreme oversold conditions. The company's financial health is concerning, with a net income loss of $24.83 million in Q2 2026 and a gross margin of only 54.99%, which is not sufficient to cover its operational costs. The primary risk is the high forward P/E ratio of 192.31, suggesting that the stock may be overvalued given its current financial performance.

Métricas de valoración

El PER previsto actual de Greenlane Holdings Inc (GNLN) es 192.31, frente a su media de 5 años de 46.55.

PER previsto

Sobrevalorado
Media 5A P/E
46.55
P/E actual
192.31
Sobrevalorada
172.30
Infravalorada
-79.21

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
2.95
EV/EBITDA actual
0.00
Sobrevalorada
17.20
Infravalorada
-11.30

Precio/ventas previsto

Valor razonable
Media 5A P/S
0.08
P/S actual
0.00
Sobrevalorada
0.20
Infravalorada
-0.04

Cronología de eventos

2026-04-09 (ET)

11:41:00

Morgan Stanley's Bitcoin ETF Attracts $34M on First Day

07:40:00

Greenlane Authorizes $2M Share Repurchase Program

2026-04-02 (ET)

20:00:00

Greenlane Holdings Trading Halted, News Pending

2026-04-01 (ET)

08:20:00

Greenlane Announces 1-for-8 Reverse Stock Split

2026-03-03 (ET)

07:50:00

Company Holds Approximately 70.4M BERA Units and Deploys 50M Units

Noticias

Preguntas frecuentes sobre GNLN, respondidas por Alphio AI

Greenlane Holdings, Inc. provides a global platform for the development and distribution of smoking accessories, vape devices, and lifestyle products to producers, processors, specialty retailers, smoke shops, convenience stores, and retail consumers. The Company operates as a family of brands, third-party brand accelerator, and an omnichannel distribution platform. The Company offers its own diverse brand portfolio and its licensed Marley Natural and K.Haring branded products. It also offers a set of third-party products through its direct sales channels and its proprietary, owned and operated e-commerce platforms. Its Greenlane Brands include Groove, its smoke shop and ancillary product brand - Higher Standards, and its child-resistant packaging brand - Pollen Gear. It merchandises vaporizers, packaging, and other ancillary products in the United States, Canada, Europe, and Latin America. Its third-party brands include Storz and Bickel, Grenco Science, PAX, and Cookies. It operates in the Consumer Non-Cyclicals sector (WHOLESALE-DURABLE GOODS, NEC industry).

Greenlane Holdings is not a good buy right now due to its current price of $1.14, a staggering year-to-date change of -90.98%, and an RSI of 9.42 indicating extreme oversold conditions. The company's financial health is concerning, with a net income loss of $24.83 million in Q2 2026 and a gross margin of only 54.99%, which is not sufficient to cover its operational costs. The primary risk is the high forward P/E ratio of 192.31, suggesting that the stock may be overvalued given its current financial performance.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar